Clinical trial • Phase III • Cardiology
coramitug for Transthyretin amyloid cardiomyopathy (ATTR-CM)
Phase III trial of coramitug for Transthyretin amyloid cardiomyopathy (ATTR-CM). 14 participants.
Overview
- Trial Therapeutic Area
- Cardiology
- Trial Disease
- Transthyretin amyloid cardiomyopathy (ATTR-CM)
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 05-05-2025
- First CTIS Authorization Date
- 01-07-2025
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 14
Eligibility
Recruits 14 No vulnerable populations selected (isVulnerablePopulationSelected=false). No further information provided in the record..
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected=false). No further information provided in the record.
Recruitment
- Planned Sample Size
- 14
- Recruitment Window Months
- 24
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 14
Netherlands
- Earliest CTIS Part Ii Submission Date
- 30-06-2025
- Latest Decision Or Authorization Date
- 20-02-2026
- Processing Time Days
- 235
- Number Of Sites
- 1
- Number Of Participants
- 14
Sites
- Site Name
- Pharmaceutical Research Associates Group B.V.
- Department Name
- Program Management
- Contact Person Name
- Renger Tiessen
- Contact Person Email
- Renger.Tiessen@iconplc.com
Sponsor
Primary sponsor
- Full Name
- Novo Nordisk A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- coramitug
Related trials
Other published trials that may interest you.
- ACORAMIDIS for Transthyretin amyloid cardiomyopathy (ATTR-CM)
- ALXN2220 for Transthyretin amyloid cardiomyopathy (ATTR-CM)
- CORAMITUG for Transthyretin amyloid cardiomyopathy (ATTR-CM)
- Acoramidis hydrochloride for Transthyretin amyloid cardiomyopathy (ATTR-CM)
- ALXN2220 for Transthyretin amyloid cardiomyopathy (ATTR-CM)